Increasing Local Competition, Decreasing Attractiveness

BMI View: We believe that despite the government's recent efforts to improve competitiveness in Mexico's pharmaceutical sector, persistent shortcomings in policy harmonisation means the country will continue to trail behind Latin America's largest economies in terms of attractiveness to drugmakers. Moreover, Mexico's modest potential for consumer demand growth and over-dependence on US economic cycles will continue to limit investment in the domestic pharmaceutical market.

To read the full article, please choose one of the following options: